US6723695B1ExpiredUtility

CTL epitopes from EBV

64
Assignee: QUEENSLAND INST MED RESPriority: Jul 10, 1997Filed: Jul 10, 1998Granted: Apr 20, 2004
Est. expiryJul 10, 2017(expired)· nominal 20-yr term from priority
Inventors:Scott BurrowsRajiv KhannaMartina Alison Sherritt
A61P 35/00A61P 43/00A61P 31/20A61P 31/12C12N 2710/16222C07K 14/005C12N 2710/16622A61K 40/46A61K 40/11A61K 39/00Y02A50/30
64
PatentIndex Score
24
Cited by
41
References
17
Claims

Abstract

The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
       1. An isolated peptide consisting of a cytotoxic T-cell epitope having an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ED NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID. NO:27) and QLTPHTKAV (SEQ ID NO:29). 
     
     
       2. The isolated peptide of  claim 1  wherein the cytotoxic T-cell epitope has an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLVDLLWLL (SEQ ID NO:3), LLLIAIWNL (SEQ ID NO:4), TLLVDLLWL (SEQ ID NO:7), RLGATIWQL (SEQ ID NO:1), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), and VLQWASLAV (SEQ ID NO:27). 
     
     
       3. The isolated peptide of  claim 2  wherein the cytotoxic T-cell epitope has an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID 
       NO:24), and VLQWASLAV (SEQ ID:NO:27).  
     
     
       4. An isolated nucleic acid comprising a nucleotide sequence encoding a peptide consisting of a cytotoxic T-cell epitope having an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). 
     
     
       5. The isolated nucleic acid as claimed in  claim 4  wherein the epitope has a sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YLQQNWWTL (SEQ ID NO:6), YFLEILWGL (SEQ ID NO:32), YLLEIWRL (SEQ ID NO:33), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ:ID NO:20), TLFIGSHVV (SEQ ID NO:24),and VLQWASLAV (SEQ ID NO:27). 
     
     
       6. The isolated nucleic acid of  claim 4  wherein the cytotoxic T-cell epitope has an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), TLLVDLLWL (SEQ ID NO:7), RLGATIWQL (SEQ ID NO. 11), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), and VLQWASLAV (SEQ ID NO:27). 
     
     
       7. The isolated nucleic acid of  claim 6  wherein the cytotoxic T-cell epitope has an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), and VLQWASLAV (SEQ ID NO:27). 
     
     
       8. The isolated nucleic acid of  claim 6  wherein the cytotoxic T-cell epitope has an amino acid sequence selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), YLQQNWWTL (SEQ ID NO:6), TLLVDLLWL (SEQ ID NO:7) and RLGATIWQL (SEQ ID NO:11). 
     
     
       9. A vaccinia virus vector comprising the isolated nucleic acid of  claim 8 . 
     
     
       10. A vector comprising an isolated nucleic acid as claimed in  claim 4 . 
     
     
       11. The vector as claimed in  claim 10  consisting of a bacterial vector. 
     
     
       12. The vector as claimed in  claim 11  wherein the bacterial vector is Salmonella spp. 
     
     
       13. The vector as claimed in  claim 10  consisting of a virus vector. 
     
     
       14. The vector as claimed in  claim 13  wherein the virus vector is selected from the group consisting of Adenovirus vector, Retrovirus vector, and Vaccinia vector. 
     
     
       15. The vector as claimed in  claim 14  wherein the Vaccinia vector is a Modified Vaccinia Ankara. 
     
     
       16. An isolated polypeptide comprising a plurality of isolated Epstein-Barr virus (EBV) CTL epitopes selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLOONWWTL (SEQ ID NO:6). LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO.4), WLLLFLAIL (SEQ ID NO:5). TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8). ILLIIALYL (SEQ ID NO:9). VLFIFGCLL (SEQ ID NO:10). RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV.(SEQ ID NO:20). TLFIGSHVV (SEQ ID NO:24). LIPETVPYI (SEQ ID NO:26). VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). 
     
     
       17. A method of preparing a composition for use in inducing CTLs in a subject, the method comprising admixing at least one peptide selected from the group consisting of YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLOQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID N0:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO;7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9). VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15). SLVIVTTFV (SEQ ID NO:17). LMIIPLINV (SEQ ID NO:20). TLFIGSHVV (SEQ ID NO:24). LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and OLTPHTKAV (SEQ ID NO:29). with a pharmaceutically acceptable carrier, diluent or excipient.

Join the waitlist — get patent alerts

Track US6723695B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.